

PREMIUM SPONSOR



PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSOR



OTHER SUPPORTERS



www.iccbh.org



IN ASSOCIATION WITH



Supporters



Alexion

www.alexion.com

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases, including hypophosphatasia (HPP).

Amgen

www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

BioMarin

www.biomarin.com

BioMarin focuses on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored.

Clementia

www.clementiapharma.com

Clementia is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for individuals affected by debilitating bone and other diseases with high unmet medical need. Palovarotene, our lead program is a novel retinoic acid receptor gamma (RAR γ) agonist that has shown potent activity in preventing ectopic bone formation as well as fibrosis in a variety of tissues, is under development for the treatment of Fibrodysplasia Ossificans Progressiva (or FOP). FOP is a

rare, severely disabling genetic disease characterized by heterotopic ossification in muscle and other connective tissues. After reporting results from its Phase 2 trial with palovarotene in FOP patients, Clementia has announced its intent to implement a Phase 3 registrational trial in this indication.

Eli Lilly

www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

European Calcified Tissue Society (ECTS)

www.ectsoc.org

The European Calcified Tissue Society (ECTS) is the major organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years the Society has acted as a forum to promote the highest levels of knowledge, research and education through its annual meetings, training courses and grants and awards. Membership of is open to any and all healthcare professionals working in the field and eager to participate in the ECTS Community and all it offers.

Ferring

www.ferring.com

Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics.

The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions.

Ferring has its own manufacturing facilities in several European countries, in South America, Israel, India and China. It is also currently building new facilities in the USA. With the acquisition of Bio-Technology General in 2005, it

Supporters



has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.

Ferring's marketing, medical services and sales teams, led by the corporate headquarters in Saint-Prex, Switzerland, operate from nearly 60 countries and employ over 6,000 people throughout the world, while treatments are available in 110 countries. This expansion has allowed Ferring to maintain a double-digit annual growth rate over the last two decades.

Kyowa Kirin in association with Ultragenyx

www.international.kyowa-kirin.com

www.ultragenyx.com

Kyowa Kirin International PLC, a subsidiary of Kyowa HAKKO Kirin (KHK), is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in Europe and the United States.

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Merck Serono

www.merckserono.com

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Mereo

www.mereobiopharma.com

Mereo is a UK-based specialty biopharma company established to acquire and develop innovative products that may not have otherwise been developed within large pharma or big biotech. These companies have become under increasing pressure to streamline R&D therefore creating opportunities for Merco.

Mereo's aim is to become a leading biopharma company focussed on speciality and rare diseases with significant unmet needs.

Mereo's initial portfolio is in respiratory, endocrinology and metabolic bone disease. Each of which has proof of efficacy data and address large unmet needs in either speciality or rare disease.

The company has advanced the respiratory and endocrinology products into Phase 2 and Phase 2b with data expected towards the end of the year and BPS 804 for Osteogenesis Imperfecta is about to start its Phase 2b study in adults. There is also an active search for new products.

Novo Nordisk

www.novonordisk.com

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.

Growth hormone is important in helping children grow. It is also plays a role in the overall health of children and adults. With over 25 years' experience, Novo Nordisk is committed to the growth hormone category.

Stratec Medizintechnik/ Novotec Medical

www.stratec-med.com

www.novotecmedical.de

Stratec Medizintechnik is the world's most successful producer of pQCT-based bone densitometry scanners for clinical and preclinical applications. Unlike in 2-dimensional absorptiometric machines pQCT derived density measures are independent of bone size. Therefore pQCT can be applied to all age groups and body sizes. Additionally geometrical properties of bone and muscle parameters can be analysed which allows a detailed diagnosis and the differentiation of disuse osteopenia from true osteoporosis.

Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). Due to the side alternating technology a natural movement similar to human gait is employed. Several studies showed the benefits in the improvement of mobility of chronically ill children.